- Home
- NBIX vs UHS Comparison
NBIX vs UHS Comparison
Compare NBIX & UHS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBIX
- UHS
- Stock Information
- Founded
- NBIX 1992
- UHS 1978
- Country
- NBIX United States
- UHS United States
- Employees
- NBIX N/A
- UHS N/A
- Industry
- NBIX Biotechnology: Biological Products (No Diagnostic Substances)
- UHS Hospital/Nursing Management
- Sector
- NBIX Health Care
- UHS Health Care
- Exchange
- NBIX Nasdaq
- UHS Nasdaq
- Market Cap
- NBIX 12.2B
- UHS 12.1B
- IPO Year
- NBIX 1996
- UHS N/A
- Fundamental
- Price
- NBIX $128.00
- UHS $188.95
- Analyst Decision
- NBIX Strong Buy
- UHS Buy
- Analyst Count
- NBIX 20
- UHS 16
- Target Price
- NBIX $163.20
- UHS $224.73
- AVG Volume (30 Days)
- NBIX 879.2K
- UHS 981.0K
- Earning Date
- NBIX 07-31-2025
- UHS 07-23-2025
- Dividend Yield
- NBIX N/A
- UHS 0.42%
- EPS Growth
- NBIX N/A
- UHS 51.30
- EPS
- NBIX 2.96
- UHS 17.80
- Revenue
- NBIX $2,412,600,000.00
- UHS $16,084,073,000.00
- Revenue This Year
- NBIX $16.29
- UHS $9.34
- Revenue Next Year
- NBIX $15.08
- UHS $5.63
- P/E Ratio
- NBIX $42.50
- UHS $10.62
- Revenue Growth
- NBIX 21.73
- UHS 9.73
- 52 Week Low
- NBIX $84.23
- UHS $153.99
- 52 Week High
- NBIX $157.98
- UHS $243.25
- Technical
- Relative Strength Index (RSI)
- NBIX 62.53
- UHS 64.31
- Support Level
- NBIX $125.02
- UHS $176.49
- Resistance Level
- NBIX $128.66
- UHS $184.41
- Average True Range (ATR)
- NBIX 2.68
- UHS 5.48
- MACD
- NBIX -0.34
- UHS 1.46
- Stochastic Oscillator
- NBIX 80.79
- UHS 98.32
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
About UHS Universal Health Services Inc.
Universal Health Services Inc owns and operates acute care hospitals, behavior health centers, surgical hospitals, ambulatory surgery centers, and radiation oncology centers. The firm operates in two segments: Acute Care Hospital Services and Behavioral Health Services. The company generates the majority of its revenue from the Acute Care Hospital Services segment. The Acute Care Hospital Services segment includes the firm's acute care hospitals, surgical hospitals, and surgery and oncology centers.